Professor Wenchao Wang

Wenchao Wang, PhD, Professor. Graduated from Beijing Medical University (now Peking University) with a BS degree; Graduate study in Indiana University, USA from 2001 to 2008, finished with a PhD degree in Molecular and Developmental Biology; Post-doctoral research in Dana-Farber Cancer Institute of USA from 2008 to 2012. Joined the High Magnetic Field Laboratory of the Chinese Academy of Sciences in 2012 as an associate professor in 2012. Main research areas include molecular biology, cancer biology, and biochemistry. Multiple publications since 2002 in international SCI journals, including Cancer Cell, Immunology, Science, Development, and PLoS Genetics, etc.

 
 
 

EDUCATION BACKGROUND

1996-2001 Peking University, Basic Medical Research Department, Beijing,China, B.S.

2001-2008 Indiana University, Molecular and Developmental Biology Department, Bloomington, Indiana, USA, Ph.D.

 

RESEARCH EXPERIENCE

2008-2012, Postdoc Fellow, Dana-Farber Cancer Institute, Pediatric Oncology Department, Boston, MA, USA. Advisor: Prof. Rani George

2012-2014, Associate Professor, High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, Anhui, P.R. China

2015-2014, Professor, High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, Anhui, P.R. China

 

PUBLICATIONS

  1. Liu F#, Wang J#, Yang X#, Li B#, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen Y, Wang L, Gray NS*, Liu J*, Zhang X*, Liu Q*. Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem. Biol. 2016, 11(6): 1537-43.
  2. Liu X#, Wang A#, Liang X#, Chen C#, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W*, Weisberg EL*, Liu J*, Liu Q*. Characterization of selective and potent PI3K╬┤ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget 2016, 7(22): 32641-51.
  3. Wang Q#, Liu F#, Wang B#, Zou F#, Chen C#, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, Wang Y, Liu J*, Liu Q*. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benz amide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-79.
  4. Wang A#, Wu H#, Chen C#, Hu C#, Qi Z#, Wang W, Yu K, Liu X, Zou F, Zhao Z, Wu J, Liu J, Liu F, Wang L, Stone RM, Galinksy IA, Griffin JD, Zhang S, Weisberg EL*, Liu J*, Liu Q*. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget 2016, 29131-42.
  5. Wu H#, Wang A#, Zhang W#, Wang B#, Chen C#, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, Zhao P, Wang J, Wang C, Weisberg EL, Gray NS, Yun CH, Liu J*, Chen L*, Liu Q*. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget 2015, 6(31): 31313-22.
  6. Wang W, Zhong Q, Teng L, Bhatnagar N, Sharma B, Zhang X, Luther W 2nd, Haynes LP, Burgoyne RD, Vidal M, Volchenboum S, Hill DE, George RE*. Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Oncogene 2014, 33(25): 3316-24.
  7. Gaydos LJ, Wang W, Strome S*. Gene repression. H3K27me and PRC2 transmit a memory of repression across generations and during development. Science 2014, 345(6203): 1515-8.
  8. Wu H#, Wang W#, Liu F#, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q*, Gray NS*. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem. Biol. 2014, 9(5): 1086-91.
  9. Pei D, Luther W, Wang W, Paw BH, Stewart RA, George RE*. Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet. 2013, 9(6): e1003533.
  10. Liu F#, Zhang X#, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP*, Liu Q*, Gray NS*. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem. Biol. 2013, 8(7): 1423-8.
  11. Zhang X, Wang W, Bedigian AV, Coughlin ML, Mitchison TJ, Eggert US*. Dopamine receptor D3 regulates endocytic sorting by a Prazosin-sensitive interaction with the coatomer COPI. Proc. Natl. Acad. Sci. USA 2012, 109(31): 12485-90.
  12. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE*. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012, 22(1): 117-30.
  13. Zhu S#, Lee JS#, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H, Stewart RA, Wang W, George RE, Kanki JP, Look AT*. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012, 21(3): 362-73.